Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 7/20 | 0.42 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.39 |
| ▸ | BAD | Q92934 | 2/20 | 0.39 |
| ▸ | IKBKB | O14920 | 2/20 | 0.39 |
| ▸ | CHUK | O15111 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6775731 | 0.94 | PLA2G2A (0.46) | PLA2G2APLA2G10PLA2G1BPLA2G5MCL1 | |
| SCHEMBL6777226 | 0.89 | ADRA1D (0.43) | PLA2G2AIKBKBCHUK | |
| SCHEMBL6894724 | 0.89 | SLC6A3 (0.48) | PLA2G2APLA2G10PLA2G1BPLA2G5PTGDR2 | |
| SCHEMBL6690216 | 0.88 | PLA2G2A (0.43) | PLA2G2APLA2G1BIKBKBCHUKPPARG | |
| SCHEMBL6770388 | 0.88 | PLA2G2A (0.41) | PLA2G2APLA2G1BIKBKBCHUKPPARG | |
| SCHEMBL6770301 | 0.87 | PLA2G2A (0.41) | PLA2G2A | |
| SCHEMBL6782583 | 0.87 | ALDH1A1 (0.41) | SUCNR1IKBKBCHUK | |
| SCHEMBL6771780 | 0.87 | IKBKB (0.37) | PLA2G2AIKBKBCHUK | |
| SCHEMBL6776614 | 0.87 | PLA2G2A (0.44) | PLA2G2ACYP2C19 | |
| SCHEMBL7954333 | 0.87 | PLA2G2A (0.54) | PLA2G2APLA2G10PLA2G1BPLA2G5PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |